LIVZON PHARMA(01513),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01513 LIVZON PHARMA

Closed 03-11 16:08:15

28.520

-0.400

-1.38%

High29.000	Low28.480	Vol616.43K
Open28.980	D1 Closing28.920	Amplitude1.80%
Mkt Cap25.33B	Tradable Cap8.56B	Total Shares888.00M
T/O17.66M	T/O Rate0.21%	Tradable Shares300.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"LIVZON PHARMA","latestPrice":28.52,"timestamp":1773216495002,"preClose":28.92,"halted":0,"volume":616429,"delay":0,"changeRate":-0.013831258644536725,"floatShares":300000000,"shares":888000000,"eps":2.239469,"marketStatus":"Closed","change":-0.4,"latestTime":"03-11 16:08:15","open":28.98,"high":29,"low":28.48,"amount":17662606,"amplitude":0.017981,"askPrice":28.6,"askSize":100,"bidPrice":28.52,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":2.606205,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773279000000},"marketStatusCode":5,"adr":0,"listingDate":1389801600000,"exchange":"SEHK","adjPreClose":28.92,"dividendRate":0.042997,"openAndCloseTimeList":[[1773192600000,1773201600000],[1773205200000,1773216000000]],"volumeRatio":0.580835,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"Livzon Pharmaceutical Group Inc.","latestPrice":34.87,"timestamp":1773212400000,"preClose":34.99,"halted":0,"volume":2933800,"delay":0,"premium":"-28.21"}},"requestUrl":"/m/hq/s/01513","defaultTab":"news","newsList":[{"id":"2618646301","title":"Vietnam Securities Regulator Approves Livzon Subsidiary's Acquisition of Imexpharm","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646301","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646301?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:25","pubTimestamp":1773044755,"startTime":"0","endTime":"0","summary":"Vietnam's securities commission approved the purchase of Livzon Pharmaceutical  subsidiary Lian SGP of Vietnam-listed Imexpharm  through a public tender.Livzon previously raised the maximum purchase price for the acquisition to 1.85 billion yuan from 1.59 billion yuan in December 2025, according to a filing by parent company Joincare Pharmaceutical  with the Shanghai bourse.The Joincare subsidiary initially offered to acquire a 64.81% stake in antibiotic and cardiovascular drug manufacturer Imexpharm in May.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","600380","000513","BK1191","01513","BK0028","BK0046","BK0187","BK0077","BK0114","BK0188"],"gpt_icon":0},{"id":"1148646401","title":"LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam","url":"https://stock-news.laohu8.com/highlight/detail?id=1148646401","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148646401?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:22","pubTimestamp":1772796162,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"1173968783","title":"LIVZON PHARMA Receives Vietnamese Regulatory Approval for IMP Share Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173968783","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173968783?lang=en_us&edition=fundamental","pubTime":"2026-03-06 18:58","pubTimestamp":1772794696,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) has announced that its overseas wholly-owned subsidiary, LIANSGP HOLDING PTE. LTD. (LIANSGP), has formally received approval documents from the Vietnamese State Securities...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","FVNmain","161027","BK1191"],"gpt_icon":0},{"id":"1130626679","title":"Livzon Pharmaceutical Group Inc. (01513) Announces Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1130626679","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130626679?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:34","pubTimestamp":1772444064,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. submitted its monthly return for the period ended 28 February 2026 on 2 March 2026. The announcement indicates no changes in total authorised share capital, with the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"1141272303","title":"Livzon Pharmaceutical Group Inc. Schedules Board Meeting to Discuss 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1141272303","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141272303?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:24","pubTimestamp":1772443464,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. 麗珠醫藥集團股份有限公司 has announced that its Board of Directors will convene on 24 March 2026. The meeting will focus on reviewing and approving the annual results for the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"1188073503","title":"Livzon Pharmaceutical Group Inc. Board and Committee Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1188073503","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188073503?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:41","pubTimestamp":1772361689,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc.* announced an update on its Board of Directors and their respective committee memberships. The Board comprises Executive Director Mr. Tang Yanggang (Vice Chairman),...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"1129488630","title":"Livzon Pharmaceutical Group Inc. Announces Board and Senior Management Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1129488630","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129488630?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:23","pubTimestamp":1772360627,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. recently issued an announcement detailing significant changes to its Board of Directors and senior management. All relevant information is drawn directly from the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"1124760033","title":"Livzon Pharmaceutical Group (01513) Releases January 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1124760033","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124760033?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:25","pubTimestamp":1770024347,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. (01513) published its Monthly Return for the period ended 31 January 2026. According to the announcement, the authorized share capital of H shares and A shares...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0},{"id":"2601803050","title":"Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803050","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803050?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:12","pubTimestamp":1767791551,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group  said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK1191","BK0188","01513","BK0187","000513","BK0239"],"gpt_icon":0},{"id":"1153150074","title":"LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=1153150074","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153150074?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:46","pubTimestamp":1767782761,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01513"],"gpt_icon":0},{"id":"1164841848","title":"LIVZON PHARMA (01513) Cancels 16.1933 Million Repurchased A-Shares on December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=1164841848","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164841848?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:36","pubTimestamp":1767613009,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced the cancellation of 16.1933 million repurchased A-shares on December 31, 2025.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399300","159982","01513","BK1191"],"gpt_icon":0},{"id":"2595574913","title":"Livzon Pharmaceutical Launches Tender Offer For Vietnam's Imexpharm, Raising Bid to 1.85 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2595574913","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595574913?lang=en_us&edition=fundamental","pubTime":"2025-12-31 09:08","pubTimestamp":1767143284,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group  has revised its previously announced acquisition of a controlling stake in Vietnam-listed Imexpharm , raising the maximum purchase price to about 1.85 billion yuan from the initial 1.59 billion yuan, triggering a mandatory tender offer.The drug company initially offered to acquire a 64.8% stake in Imexpharm in May. The target company specializes in antibiotics and cardiovascular drugs.Following the revision, the timeline of the deal has been extended to June 30, 2026, from the initial February 2026 deadline, Livzon parent Joincare Pharmaceutical Group Industry  said in a Shanghai Stock Exchange filing on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0114","BK0077","000513","BK0239","BK0187","BK0188","600380","BK1191","BK0046","01513","BK0028"],"gpt_icon":0},{"id":"2595749652","title":"Joincare Pharmaceutical to Divest 49% Stake in Animal Health Unit For 51.5 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2595749652","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595749652?lang=en_us&edition=fundamental","pubTime":"2025-12-31 09:01","pubTimestamp":1767142893,"startTime":"0","endTime":"0","summary":"Joincare Pharmaceutical Group Industry  plans to divest its entire 49% stake in its animal health subsidiary for 51.5 million yuan to focus on its core business areas.The Chinese pharmaceutical company will sell the stake in Maohaizi Animal Health  to its related party, Shenzhen Xinyou Maohai Investment Partnership .Post-transaction, Xinyou Maohai will hold 52.6% of Maohaizi's equity, while Joincare's controlling shareholder, Livzon Pharmaceutical Group Co., the parent company of Livzon Pharmaceutical Group Inc. , will hold the remaining 47.4% stake.Joincare Pharmaceutical will no longer directly hold any stake in the animal health company following the transaction.The company cited the \"weak synergy\" between Maohaizi's main business and the company's strategy as the reason for the divestment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK0239","01513","BK0028","600380","BK0077","000513","BK0114","BK0188","BK0187","BK0046"],"gpt_icon":0},{"id":"1146537907","title":"LIVZON PHARMA (01513): Joincare to Transfer 49% Stake in Mao Haizi to Xin You Mao Hai","url":"https://stock-news.laohu8.com/highlight/detail?id=1146537907","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146537907?lang=en_us&edition=fundamental","pubTime":"2025-12-30 19:04","pubTimestamp":1767092674,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that on December 30, 2025, the company, its controlling shareholder Joincare Pharmaceutical Group Industry Co.,Ltd., Xin You Mao Hai, and Mao Haizi entered into a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","600380","BK0114","BK1191","BK0239","BK0188","BK0046","BK0028","01513"],"gpt_icon":0},{"id":"1113128497","title":"LIVZON PHARMA (01513) Appoints Xia Yu as Company's Securities Affairs Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1113128497","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113128497?lang=en_us&edition=fundamental","pubTime":"2025-12-30 18:58","pubTimestamp":1767092298,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that the board of directors of Livzon Pharmaceutical Group Co., Ltd. recently received the resignation letter from the company's Securities Affairs Representative, Ms....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01513","161027"],"gpt_icon":0},{"id":"1187420572","title":"LIVZON PHARMA (01513) Submits LZM012/XKH004 for Market Approval in Plaque Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1187420572","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187420572?lang=en_us&edition=fundamental","pubTime":"2025-12-24 14:13","pubTimestamp":1766556825,"startTime":"0","endTime":"0","summary":"On December 24, CDE's website revealed that LIVZON PHARMA (01513), in collaboration with Xinkanghe Biotech, has submitted an application for the market approval of LZM012/XKH004 (Lekangqituzumab) for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","BK1191"],"gpt_icon":0},{"id":"1110495698","title":"LIVZON PHARMA (01513): NS-041 Tablets Granted Clinical Trial Approval for Additional Indication of Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1110495698","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110495698?lang=en_us&edition=fundamental","pubTime":"2025-12-21 18:36","pubTimestamp":1766313377,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that its wholly-owned subsidiary, Livzon Pharmaceutical Factory, has received the Drug Clinical Trial Approval Notice (Notice No.: 2025LP03436, 2025LP03437) from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01513"],"gpt_icon":0},{"id":"1138230135","title":"LIVZON PHARMA (01513) Elects Wang Zhiyao as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1138230135","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138230135?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:12","pubTimestamp":1765368731,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that during its first extraordinary general meeting held on December 10, 2025, the company approved the proposal to appoint Ms. Wang Zhiyao as an independent...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","BK1191"],"gpt_icon":0},{"id":"1163080994","title":"LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1163080994","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163080994?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:06","pubTimestamp":1765188385,"startTime":"0","endTime":"0","summary":"LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the \"National Reimbursement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513","BK1191"],"gpt_icon":0},{"id":"1189636358","title":"Livzon Pharmaceutical Group Inc. (01513.HK, 000513.SZ) Releases November 2025 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1189636358","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189636358?lang=en_us&edition=fundamental","pubTime":"2025-12-01 17:06","pubTimestamp":1764579986,"startTime":"0","endTime":"0","summary":"Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01513"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.livzon.com.cn","stockEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":-0.0136},{"period":"3month","weight":-0.053},{"period":"6month","weight":-0.2128},{"period":"1year","weight":0.1749},{"period":"ytd","weight":0.014}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":-0.0226},{"period":"3month","weight":0.0164},{"period":"6month","weight":-0.0048},{"period":"1year","weight":0.0915},{"period":"ytd","weight":0.0129}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Livzon Pharmaceutical Group Inc is a China-based company principally engaged in the research, development, production and sale of pharmaceutical products. The Company's main businesses include chemical drug preparations, biological products, active pharmaceutical ingredients and intermediates, traditional Chinese medicine preparations, diagnostic reagents and equipment, commercial development and functional management. The Company's main products include Ilaprazole (Ilaprazole Enteric-Coated Tablets and Ilaprazole Sodium for Injection), a series of Bismuth Potassium Citrate products, Rabeprazole Sodium Enteric-Coated Capsules, Weisanlian (Bismuth Potassium Citrate Tablets/Tinidazole Tablets/Clarithromycin Tablets), Leuprorelin Acetate Microspheres for Injection, Urofollitropin for Injection, Menotropins for Injection, Voriconazole for Injection and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001134},{"month":2,"riseRate":0.538462,"avgChangeRate":0.025407},{"month":3,"riseRate":0.538462,"avgChangeRate":0.026406},{"month":4,"riseRate":0.666667,"avgChangeRate":0.03227},{"month":5,"riseRate":0.416667,"avgChangeRate":0.013787},{"month":6,"riseRate":0.5,"avgChangeRate":0.000101},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.018444},{"month":8,"riseRate":0.5,"avgChangeRate":0.000715},{"month":9,"riseRate":0.454545,"avgChangeRate":0.011936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.019823},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03425},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008149}],"exchange":"SEHK","name":"LIVZON PHARMA","nameEN":"LIVZON PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LIVZON PHARMA(01513),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LIVZON PHARMA(01513) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LIVZON PHARMA,01513,LIVZON PHARMA股票,LIVZON PHARMA股票老虎,LIVZON PHARMA股票老虎国际,LIVZON PHARMA行情,LIVZON PHARMA股票行情,LIVZON PHARMA股价,LIVZON PHARMA股市,LIVZON PHARMA股票价格,LIVZON PHARMA股票交易,LIVZON PHARMA股票购买,LIVZON PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LIVZON PHARMA(01513),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LIVZON PHARMA(01513) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}